Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations

梁晓华; 黄若凡; 詹　琼

doi:10.19401/j.cnki.1007-3639.2019.01.011

您当前的位置：

首页 >

文章列表页 >

Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations

更新时间：2026-01-27

- Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations
- China Oncology Vol. 29, Issue 1, Pages: 71-80(2019)
- 作者机构：
  
  复旦大学附属华山医院肿瘤科,上海,200040
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.01.011
  CLC： R734.2
- Published Online：01 February 2019，
  
  Published：01 February 2019
- 稿件说明：
移动端阅览
梁晓华,黄若凡,詹　琼. 驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）[J]. 中国癌症杂志, 2019, 29(1): 71-80.

梁晓华, 黄若凡, 詹　琼. Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations[J]. China Oncology, 2019, 29(1): 71-80.
梁晓华,黄若凡,詹　琼. 驱动基因阳性非小细胞肺癌脑转移诊治上海专家共识（2019年版）[J]. 中国癌症杂志, 2019, 29(1): 71-80. DOI： 10.19401/j.cnki.1007-3639.2019.01.011.

梁晓华, 黄若凡, 詹　琼. Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations[J]. China Oncology, 2019, 29(1): 71-80. DOI： 10.19401/j.cnki.1007-3639.2019.01.011.

摘要

驱动基因阳性非小细胞肺癌（non-small cell lung cancer，NSCLC）脑转移是临床关注的热点，综合治疗是原则，不同治疗手段的合理组合和顺序安排，对延长患者生存期和提高生活质量有着重要意义。上海市抗癌协会脑转移瘤专业委员会组织专家制订了本共识，以规范驱动基因阳性NSCLC脑转移的诊治。

Abstract

Brain metastasis of non-small cell lung cancer (NSCLC) with driver gene mutation is becoming a clinical highlight. Rational combination and sequencing of different treatment methods are of great significance for prolonging the survival time and improving the quality of life of patients. Experts from the Committee of Brain Metastases

Shanghai Anti-Cancer Association have formulated this consensus to standardize the diagnosis and treatment of brain metastasis from NSCLC with driver gene mutation.

关键词

Keywords

references

Views

4526

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Important clinical research progress in lung cancer in 2022

Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Treatment strategies and prognostic analysis of 87 patients with salivary duct carcinoma: a retrospective cohort study

Related Author

Chunxia SU

Caicun ZHOU

Silai YU

Jianjiao NI

Zhengfei ZHU

LU Ye

ZHANG Wenxiang

KONG Xiangyi

Related Institution

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

School of Basic Medical Sciences, Shanghai Medical College, Fudan University

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Institute of Thoracic Oncology, Fudan University

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

AI问答

⁰